National Institute on Aging – Developmental Therapeutics Review – Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: N6CD0E39941EN
Leaflet:

Download PDF Leaflet

National Institute on Aging – Developmental Therapeutics Review – Q4 2010
Summary

Global Market Direct’s pharmaceuticals report, “National Institute on Aging – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable). It also gives a complete picture of the institute’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by National Institute on Aging.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of National Institute on Aging with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of National Institute on Aging’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in National Institute on Aging’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate National Institute on Aging’s position with total access to a detailed intelligence on its therapeutic products development.
- Assess the growth potential of National Institute on Aging in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with National Institute on Aging.
- Avoid Intellectual Property Rights related issues.
- Undertake deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 NATIONAL INSTITUTE ON AGING - RESEARCH AND DEVELOPMENT OVERVIEW

3.1 Key Therapeutic Areas

4 NATIONAL INSTITUTE ON AGING - INVESTIGATIONAL PRODUCTS REVIEW

4.1 Products by Stage of Development
4.2 Products - Monotherapy
4.3 Products - Combination Treatment Modalities

5 NATIONAL INSTITUTE ON AGING - INVESTIGATIONAL PRODUCTS GLANCE

5.1 National Institute on Aging - Phase III Products
5.2 National Institute on Aging - Phase II Products
5.3 National Institute on Aging - Phase I Products
5.4 National Institute on Aging - Pre-Clinical and Discovery Products

6 NATIONAL INSTITUTE ON AGING - DRUG PROFILES

6.1 Product 1 - Product Profile
  6.1.1 Product Description
  6.1.2 Mechanism of Action
  6.1.3 R&D Progress

7 NATIONAL INSTITUTE ON AGING - INVESTIGATIONAL PRODUCTS ANALYSIS

7.1 National Institute on Aging Products by Therapeutic Class
7.2 National Institute on Aging Products by Target
7.3 National Institute on Aging by Route of Administration
7.4 National Institute on Aging Products by Molecule Type

8 NATIONAL INSTITUTE ON AGING - RECENT PRODUCT UPDATES
9 NATIONAL INSTITUTE ON AGING - FEATURED NEWS
10 NATIONAL INSTITUTE ON AGING - LOCATIONS
11 APPENDIX

11.1 Global Markets Direct Research Methodology
11.2 Coverage
11.3 Secondary Research
11.4 Primary Research
11.5 Models
11.6 Expert Panels
11.7 Contact Us
11.8 Disclaimer

LIST OF TABLES

Table 1: National Institute on Aging - Key Therapeutic Areas
Table 2: National Institute on Aging - Products by Stage of Development,
Table 3: National Institute on Aging - Monotherapy Products under Investigation,
Table 4: National Institute on Aging - Combination Treatment Modalities under Investigation,
Table 5: National Institute on Aging - Phase III Products,
Table 6: National Institute on Aging - Phase II Products,
Table 7: National Institute on Aging - Phase I Products,
Table 8: National Institute on Aging - Pre-Clinical and Discovery Products,
Table 9: National Institute on Aging - Products By Therapeutic Class
Table 10: National Institute on Aging - Products By Target
Table 11: National Institute on Aging - Products By Route of Administration
Table 12: National Institute on Aging - Products By Molecule Type
Table 13: National Institute on Aging - Recent Product Updates

LIST OF FIGURES

Figure 1: National Institute on Aging - Research and Development Overview
Figure 2: National Institute on Aging - Products by Stage of Development,
Figure 3: National Institute on Aging - Monotherapy Products,
Figure 4: National Institute on Aging - Combination Treatment Modalities,
Figure 5: National Institute on Aging - Products By Therapeutic Class and Stage of Development
Figure 6: National Institute on Aging - Products By Therapeutic Class
Figure 7: National Institute on Aging - Products By Target and Stage of Development
Figure 8: National Institute on Aging - Products By Target
Figure 9: National Institute on Aging - Products By Route of Administration and Stage of Development
Figure 10: National Institute on Aging - Products By Route of Administration
Figure 11: National Institute on Aging - Products By Molecule Type and Stage of Development
Figure 12: National Institute on Aging - Products By Molecule Type

COMPANIES MENTIONED

National Institute on Aging

Ask Your Question

National Institute on Aging – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: